# Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B

> **NCT02249988** · PHASE2,PHASE3 · COMPLETED · sponsor: **Abivax S.A.** · enrollment: 261 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** ABX203 therapeutic Hepatitis B vaccine treatment arm

## Key facts

- **NCT ID:** NCT02249988
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2017-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02249988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02249988, "Clinical Efficacy of ABX203 Therapeutic Vaccine in HBeAg Negative Patients With Chronic Hepatitis B". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02249988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*